Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 204

Similar articles for PubMed (Select 16779793)

1.

Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma.

Kushner BH, Budnick A, Kramer K, Modak S, Cheung NK.

Cancer. 2006 Jul 15;107(2):417-22.

2.

Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group.

Landier W, Knight K, Wong FL, Lee J, Thomas O, Kim H, Kreissman SG, Schmidt ML, Chen L, London WB, Gurney JG, Bhatia S.

J Clin Oncol. 2014 Feb 20;32(6):527-34. doi: 10.1200/JCO.2013.51.2038. Epub 2014 Jan 13.

3.

[The "Muenster classification" of high frequency hearing loss following cisplatin chemotherapy].

Schmidt CM, Bartholomäus E, Deuster D, Heinecke A, Dinnesen AG.

HNO. 2007 Apr;55(4):299-306. German.

PMID:
16437215
4.

The incidence of hearing impairment after successful treatment of neuroblastoma.

Simon T, Hero B, Dupuis W, Selle B, Berthold F.

Klin Padiatr. 2002 Jul-Aug;214(4):149-52.

PMID:
12165893
5.

Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.

Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N, Hartmann O.

J Pediatr Hematol Oncol. 2004 Oct;26(10):649-55.

PMID:
15454836
6.

[Detection of late ototoxic side effect of cisplatin by distortion otoacoustic emission (DPOAE)].

Biró K, Noszek L, Prekopp P, Nagyiványi K, Géczi L, Gaudi I, Bodrogi I.

Magy Onkol. 2006;50(4):329-35. Epub 2007 Jan 10. Hungarian.

7.

Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.

Lanvers-Kaminsky C, Krefeld B, Dinnesen AG, Deuster D, Seifert E, Würthwein G, Jaehde U, Pieck AC, Boos J.

Pediatr Blood Cancer. 2006 Aug;47(2):183-93.

PMID:
16302218
8.

Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.

Marina N, Chang KW, Malogolowkin M, London WB, Frazier AL, Womer RB, Rescorla F, Billmire DF, Davis MM, Perlman EJ, Giller R, Lauer SJ, Olson TA; Children's Oncology Group.

Cancer. 2005 Aug 15;104(4):841-7.

9.

Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer.

Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA, Kanz L.

Br J Cancer. 1998 Apr;77(8):1355-62.

11.

Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system.

Stöhr W, Langer T, Kremers A, Bielack S, Lamprecht-Dinnesen A, Frey E, Beck JD; German Late Effects Working Group in the German Society of Pediatric Oncology and Hematology.

Cancer Invest. 2005;23(3):201-7.

PMID:
15945505
12.

Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma.

Parsons SK, Neault MW, Lehmann LE, Brennan LL, Eickhoff CE, Kretschmar CS, Diller LR.

Bone Marrow Transplant. 1998 Oct;22(7):669-74.

13.

Ototoxicity in children treated for osteosarcoma.

Lewis MJ, DuBois SG, Fligor B, Li X, Goorin A, Grier HE.

Pediatr Blood Cancer. 2009 Mar;52(3):387-91. doi: 10.1002/pbc.21875.

PMID:
19061216
14.

Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.

Reavis KM, Phillips DS, Fausti SA, Gordon JS, Helt WJ, Wilmington D, Bratt GW, Konrad-Martin D.

Ear Hear. 2008 Dec;29(6):875-93. doi: 10.1097/AUD.0b013e318181ad99.

PMID:
18753950
15.

[Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention].

Montaguti M, Brandolini C, Ferri GG, Hatzopoulos S, Prete A, Pession A.

Acta Otorhinolaryngol Ital. 2002 Feb;22(1):14-8. Italian.

PMID:
12236007
16.

Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients.

Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J.

Pediatr Blood Cancer. 2012 Jul 15;59(1):144-8. doi: 10.1002/pbc.24138. Epub 2012 Mar 19.

17.

Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma.

Jehanne M, Lumbroso-Le Rouic L, Savignoni A, Aerts I, Mercier G, Bours D, Desjardins L, Doz F.

Pediatr Blood Cancer. 2009 May;52(5):637-43. doi: 10.1002/pbc.21898.

PMID:
19148943
18.

Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens.

Dean JB, Hayashi SS, Albert CM, King AA, Karzon R, Hayashi RJ.

J Pediatr Hematol Oncol. 2008 Feb;30(2):130-4. doi: 10.1097/MPH.0b013e31815d1d83.

PMID:
18376265
19.

Response to N7 induction chemotherapy in children more than one year of age diagnosed with metastatic neuroblastoma treated in UKCCSG centers.

Kohler JA, Ellershaw C, Machin D; Neuroblastoma Working Group of the Children's Cancer and Leukaemia Group.

Pediatr Blood Cancer. 2007 Sep;49(3):234-9.

PMID:
17252561
20.

Assessment of cisplatin-induced ototoxicity using derived-band ABRs.

Coupland SG, Ponton CW, Eggermont JJ, Bowen TJ, Grant RM.

Int J Pediatr Otorhinolaryngol. 1991 Oct;22(3):237-48.

PMID:
1752735
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk